AN2 Therapeutics EBIT

The latest EBIT for ANTX is $-38M as of June 2026. That compares with $-41M in the prior-year period — up 9.2% year over year. That is below the sector sector average of $-6.4M. Investors often review this figure alongside AN2 Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANTX's EBIT moved from $-41M to $-38M — a 9.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AN2 Therapeutics's operating scale or balance-sheet position.

Against its sector companies, ANTX currently prints $-38M for EBIT, while the sector average sits near $-6.4M. That is roughly 486.8% below the sector mean. Large gaps often invite a closer look at AN2 Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-38M for ANTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting ANTX's EBIT ($-38M), review year-over-year change from $-41M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.